Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer
F-fluorodeoxyglucose positron emission tomography-computed tomography ( F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of F-FDG-PET/CT for thyroid cancer is co...
Gespeichert in:
| Veröffentlicht in: | Auris, nasus, larynx nasus, larynx, 2024-08, Vol.51 (4), p.696 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 696 |
| container_title | Auris, nasus, larynx |
| container_volume | 51 |
| creator | Yoshikawa, Tomomi Endo, Kazuhira Moriyama-Kita, Makiko Ueno, Takayoshi Nakanishi, Yosuke Dochi, Hirotomo Uno, Daisuke Kondo, Satoru Yoshizaki, Tomokazu |
| description | F-fluorodeoxyglucose positron emission tomography-computed tomography (
F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of
F-FDG-PET/CT for thyroid cancer is controversial. However, uptake of
F-FDG and the corresponding maximum standardized uptake value (SUVmax) is expected to reflect the metabolic status of cancer cells. In the present study, we sought to determine the relationship between
F-FDG uptake and tumor metabolism- associated factors.
This was a single-center retrospective study. In the present study, SUVmax was compared with the expression of hexokinase 2 (HK2), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF), and glutaminase 1 (GLS1) in 41 patients with thyroid cancer.
GLS1 expression was found to be moderately correlated with SUVmax (p < 0.001, r = 0.51), whereas HK2 and VEGF expression were weakly correlated (p = 0.011, r = 0.28, p = 0.008, r = 0.29, respectively) and GLUT1 did not correlate with SUVmax (p = 0.62, r = 0.06).
Our findings suggest
F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_38733874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38733874</sourcerecordid><originalsourceid>FETCH-pubmed_primary_387338743</originalsourceid><addsrcrecordid>eNqFzs2KwjAUBeAgyPg3ryD3BQotEVuXwzAyDzB7iemtRm96Q27C2I3Pbhe6dnE4m_PBmah51dS7otrU25laiFzKstS13n2omW5qPWYzV_cvEbbOJMc9cAdVA_sCOsocuUW-DSfKlgUhh2SuCP8unSGdEfAWIoo8mcdkjkxOfBGRTMIWPBPaTCjgeggmOCITh9EOkV0L1vQW40pNO0OCn89eqvX-5-_7twj56LE9hOj8qA6vw_rt4AHAbU5k</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Yoshikawa, Tomomi ; Endo, Kazuhira ; Moriyama-Kita, Makiko ; Ueno, Takayoshi ; Nakanishi, Yosuke ; Dochi, Hirotomo ; Uno, Daisuke ; Kondo, Satoru ; Yoshizaki, Tomokazu</creator><creatorcontrib>Yoshikawa, Tomomi ; Endo, Kazuhira ; Moriyama-Kita, Makiko ; Ueno, Takayoshi ; Nakanishi, Yosuke ; Dochi, Hirotomo ; Uno, Daisuke ; Kondo, Satoru ; Yoshizaki, Tomokazu</creatorcontrib><description>F-fluorodeoxyglucose positron emission tomography-computed tomography (
F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of
F-FDG-PET/CT for thyroid cancer is controversial. However, uptake of
F-FDG and the corresponding maximum standardized uptake value (SUVmax) is expected to reflect the metabolic status of cancer cells. In the present study, we sought to determine the relationship between
F-FDG uptake and tumor metabolism- associated factors.
This was a single-center retrospective study. In the present study, SUVmax was compared with the expression of hexokinase 2 (HK2), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF), and glutaminase 1 (GLS1) in 41 patients with thyroid cancer.
GLS1 expression was found to be moderately correlated with SUVmax (p < 0.001, r = 0.51), whereas HK2 and VEGF expression were weakly correlated (p = 0.011, r = 0.28, p = 0.008, r = 0.29, respectively) and GLUT1 did not correlate with SUVmax (p = 0.62, r = 0.06).
Our findings suggest
F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment.</description><identifier>EISSN: 1879-1476</identifier><identifier>PMID: 38733874</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Adult ; Aged ; Carcinoma, Papillary - diagnostic imaging ; Carcinoma, Papillary - metabolism ; Female ; Fluorodeoxyglucose F18 ; Glucose Transporter Type 1 - metabolism ; Glutaminase - metabolism ; Hexokinase - metabolism ; Humans ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Radiopharmaceuticals ; Retrospective Studies ; Thyroid Cancer, Papillary - diagnostic imaging ; Thyroid Cancer, Papillary - metabolism ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - metabolism ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>Auris, nasus, larynx, 2024-08, Vol.51 (4), p.696</ispartof><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38733874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshikawa, Tomomi</creatorcontrib><creatorcontrib>Endo, Kazuhira</creatorcontrib><creatorcontrib>Moriyama-Kita, Makiko</creatorcontrib><creatorcontrib>Ueno, Takayoshi</creatorcontrib><creatorcontrib>Nakanishi, Yosuke</creatorcontrib><creatorcontrib>Dochi, Hirotomo</creatorcontrib><creatorcontrib>Uno, Daisuke</creatorcontrib><creatorcontrib>Kondo, Satoru</creatorcontrib><creatorcontrib>Yoshizaki, Tomokazu</creatorcontrib><title>Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer</title><title>Auris, nasus, larynx</title><addtitle>Auris Nasus Larynx</addtitle><description>F-fluorodeoxyglucose positron emission tomography-computed tomography (
F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of
F-FDG-PET/CT for thyroid cancer is controversial. However, uptake of
F-FDG and the corresponding maximum standardized uptake value (SUVmax) is expected to reflect the metabolic status of cancer cells. In the present study, we sought to determine the relationship between
F-FDG uptake and tumor metabolism- associated factors.
This was a single-center retrospective study. In the present study, SUVmax was compared with the expression of hexokinase 2 (HK2), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF), and glutaminase 1 (GLS1) in 41 patients with thyroid cancer.
GLS1 expression was found to be moderately correlated with SUVmax (p < 0.001, r = 0.51), whereas HK2 and VEGF expression were weakly correlated (p = 0.011, r = 0.28, p = 0.008, r = 0.29, respectively) and GLUT1 did not correlate with SUVmax (p = 0.62, r = 0.06).
Our findings suggest
F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Papillary - diagnostic imaging</subject><subject>Carcinoma, Papillary - metabolism</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose Transporter Type 1 - metabolism</subject><subject>Glutaminase - metabolism</subject><subject>Hexokinase - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Thyroid Cancer, Papillary - diagnostic imaging</subject><subject>Thyroid Cancer, Papillary - metabolism</subject><subject>Thyroid Neoplasms - diagnostic imaging</subject><subject>Thyroid Neoplasms - metabolism</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>1879-1476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFzs2KwjAUBeAgyPg3ryD3BQotEVuXwzAyDzB7iemtRm96Q27C2I3Pbhe6dnE4m_PBmah51dS7otrU25laiFzKstS13n2omW5qPWYzV_cvEbbOJMc9cAdVA_sCOsocuUW-DSfKlgUhh2SuCP8unSGdEfAWIoo8mcdkjkxOfBGRTMIWPBPaTCjgeggmOCITh9EOkV0L1vQW40pNO0OCn89eqvX-5-_7twj56LE9hOj8qA6vw_rt4AHAbU5k</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Yoshikawa, Tomomi</creator><creator>Endo, Kazuhira</creator><creator>Moriyama-Kita, Makiko</creator><creator>Ueno, Takayoshi</creator><creator>Nakanishi, Yosuke</creator><creator>Dochi, Hirotomo</creator><creator>Uno, Daisuke</creator><creator>Kondo, Satoru</creator><creator>Yoshizaki, Tomokazu</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>202408</creationdate><title>Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer</title><author>Yoshikawa, Tomomi ; Endo, Kazuhira ; Moriyama-Kita, Makiko ; Ueno, Takayoshi ; Nakanishi, Yosuke ; Dochi, Hirotomo ; Uno, Daisuke ; Kondo, Satoru ; Yoshizaki, Tomokazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_387338743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Papillary - diagnostic imaging</topic><topic>Carcinoma, Papillary - metabolism</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose Transporter Type 1 - metabolism</topic><topic>Glutaminase - metabolism</topic><topic>Hexokinase - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Thyroid Cancer, Papillary - diagnostic imaging</topic><topic>Thyroid Cancer, Papillary - metabolism</topic><topic>Thyroid Neoplasms - diagnostic imaging</topic><topic>Thyroid Neoplasms - metabolism</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshikawa, Tomomi</creatorcontrib><creatorcontrib>Endo, Kazuhira</creatorcontrib><creatorcontrib>Moriyama-Kita, Makiko</creatorcontrib><creatorcontrib>Ueno, Takayoshi</creatorcontrib><creatorcontrib>Nakanishi, Yosuke</creatorcontrib><creatorcontrib>Dochi, Hirotomo</creatorcontrib><creatorcontrib>Uno, Daisuke</creatorcontrib><creatorcontrib>Kondo, Satoru</creatorcontrib><creatorcontrib>Yoshizaki, Tomokazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Auris, nasus, larynx</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshikawa, Tomomi</au><au>Endo, Kazuhira</au><au>Moriyama-Kita, Makiko</au><au>Ueno, Takayoshi</au><au>Nakanishi, Yosuke</au><au>Dochi, Hirotomo</au><au>Uno, Daisuke</au><au>Kondo, Satoru</au><au>Yoshizaki, Tomokazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer</atitle><jtitle>Auris, nasus, larynx</jtitle><addtitle>Auris Nasus Larynx</addtitle><date>2024-08</date><risdate>2024</risdate><volume>51</volume><issue>4</issue><spage>696</spage><pages>696-</pages><eissn>1879-1476</eissn><abstract>F-fluorodeoxyglucose positron emission tomography-computed tomography (
F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of
F-FDG-PET/CT for thyroid cancer is controversial. However, uptake of
F-FDG and the corresponding maximum standardized uptake value (SUVmax) is expected to reflect the metabolic status of cancer cells. In the present study, we sought to determine the relationship between
F-FDG uptake and tumor metabolism- associated factors.
This was a single-center retrospective study. In the present study, SUVmax was compared with the expression of hexokinase 2 (HK2), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF), and glutaminase 1 (GLS1) in 41 patients with thyroid cancer.
GLS1 expression was found to be moderately correlated with SUVmax (p < 0.001, r = 0.51), whereas HK2 and VEGF expression were weakly correlated (p = 0.011, r = 0.28, p = 0.008, r = 0.29, respectively) and GLUT1 did not correlate with SUVmax (p = 0.62, r = 0.06).
Our findings suggest
F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment.</abstract><cop>Netherlands</cop><pmid>38733874</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1879-1476 |
| ispartof | Auris, nasus, larynx, 2024-08, Vol.51 (4), p.696 |
| issn | 1879-1476 |
| language | eng |
| recordid | cdi_pubmed_primary_38733874 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Carcinoma, Papillary - diagnostic imaging Carcinoma, Papillary - metabolism Female Fluorodeoxyglucose F18 Glucose Transporter Type 1 - metabolism Glutaminase - metabolism Hexokinase - metabolism Humans Male Middle Aged Positron Emission Tomography Computed Tomography Radiopharmaceuticals Retrospective Studies Thyroid Cancer, Papillary - diagnostic imaging Thyroid Cancer, Papillary - metabolism Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - metabolism Vascular Endothelial Growth Factor A - metabolism |
| title | Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A57%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%2018%20F-%20fluorodeoxyglucose%20uptake%20with%20the%20expression%20of%20metabolism-related%20molecules%20in%20papillary%20thyroid%20cancer&rft.jtitle=Auris,%20nasus,%20larynx&rft.au=Yoshikawa,%20Tomomi&rft.date=2024-08&rft.volume=51&rft.issue=4&rft.spage=696&rft.pages=696-&rft.eissn=1879-1476&rft_id=info:doi/&rft_dat=%3Cpubmed%3E38733874%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38733874&rfr_iscdi=true |